These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 29223956)

  • 21. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
    Bays HE; Braeckman RA; Ballantyne CM; Kastelein JJ; Otvos JD; Stirtan WG; Soni PN
    J Clin Lipidol; 2012; 6(6):565-72. PubMed ID: 23312052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size.
    Tani S; Matsumoto M; Nagao K; Hirayama A
    J Cardiol; 2014 Jan; 63(1):60-8. PubMed ID: 24016623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
    Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial.
    Hoshi RA; Alotaibi M; Liu Y; Watrous JD; Ridker PM; Glynn RJ; Serhan CN; Luttmann-Gibson H; Moorthy MV; Jain M; Demler OV; Mora S
    Arterioscler Thromb Vasc Biol; 2024 Jul; 44(7):e196-e206. PubMed ID: 38841856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paradoxical association of lipoprotein measures with incident atrial fibrillation.
    Mora S; Akinkuolie AO; Sandhu RK; Conen D; Albert CM
    Circ Arrhythm Electrophysiol; 2014 Aug; 7(4):612-9. PubMed ID: 24860180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum cholesterol and triglyceride reference ranges of twenty lipoprotein subclasses for healthy Japanese men and women.
    Furusyo N; Ai M; Okazaki M; Ikezaki H; Ihara T; Hayashi T; Hiramine S; Ura K; Kohzuma T; Schaefer EJ; Hayashi J
    Atherosclerosis; 2013 Dec; 231(2):238-45. PubMed ID: 24267234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study.
    Hussain A; Sun C; Selvin E; Nambi V; Coresh J; Jia X; Ballantyne CM; Hoogeveen RC
    Eur J Prev Cardiol; 2022 Mar; 29(2):e53-e64. PubMed ID: 33580780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.
    Hoogeveen RC; Ballantyne CM
    Clin Chem; 2021 Jan; 67(1):143-153. PubMed ID: 33257928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia.
    Goldberg RB; Rosenson RS; Hernandez-Triana E; Misir S; Jones MR
    Diab Vasc Dis Res; 2013 May; 10(3):256-62. PubMed ID: 23152373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism.
    Walsh BW; Sacks FM
    J Clin Invest; 1993 May; 91(5):2126-32. PubMed ID: 8486779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of plasminogen activator inhibitor-1 and low-density lipoprotein heterogeneity as a risk factor of atherosclerotic cardiovascular disease with triglyceride metabolic disorder: a pilot cross-sectional study.
    Iida K; Tani S; Atsumi W; Yagi T; Kawauchi K; Matsumoto N; Hirayama A
    Coron Artery Dis; 2017 Nov; 28(7):577-587. PubMed ID: 28692480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations.
    Srisawasdi P; Vanavanan S; Rochanawutanon M; Pornsuriyasak P; Tantrakul V; Kruthkul K; Kotani K
    Clin Biochem; 2013 Oct; 46(15):1509-15. PubMed ID: 23830843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
    Ridker PM; MacFadyen JG; Glynn RJ; Chasman DI
    Circ Cardiovasc Genet; 2011 Jun; 4(3):312-7. PubMed ID: 21493817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased large VLDL and small LDL particles are related to lower bilirubin in Type 2 diabetes mellitus.
    Dullaart RP; de Vries R; Lefrandt JD
    Clin Biochem; 2014 Nov; 47(16-17):170-5. PubMed ID: 25149194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial.
    Akinkuolie AO; Glynn RJ; Padmanabhan L; Ridker PM; Mora S
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27413042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study.
    Quispe R; Elshazly MB; Zhao D; Toth PP; Puri R; Virani SS; Blumenthal RS; Martin SS; Jones SR; Michos ED
    Eur J Prev Cardiol; 2020 Oct; 27(15):1597-1605. PubMed ID: 31291776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
    Boekholdt SM; Hovingh GK; Mora S; Arsenault BJ; Amarenco P; Pedersen TR; LaRosa JC; Waters DD; DeMicco DA; Simes RJ; Keech AC; Colquhoun D; Hitman GA; Betteridge DJ; Clearfield MB; Downs JR; Colhoun HM; Gotto AM; Ridker PM; Grundy SM; Kastelein JJ
    J Am Coll Cardiol; 2014 Aug; 64(5):485-94. PubMed ID: 25082583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2.
    Shah CP; Shah BP; Dani SI; Channa BB; Lakshmanan SS; Krishnamani NC; Mehta A; Moorthy P
    Indian Heart J; 2016; 68(6):766-771. PubMed ID: 27931543
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.